The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
Open accessAbstract
Background The selective TRK inhibitor larotrectinib was approved for paediatric and adult patients with advanced TRK fusion-positive solid tumours based on a primary analysis set of 55 patients. The aim of our analysis was to explore the efficacy and long-term safety of larotrectinib in a larger population of patients with TRK fusion-positive solid tumours.Methods Patients were enrolled and treated in a phase 1 adult, a phase 1/2 paediatric, or a phase 2 adolescent and adult trial. Some eligibility criteria differed between these studies. For this pooled analysis, eligible patients were aged 1 month or older, with a locally advanced or metastatic non-CNS primary, TRK fusion-positive solid tumour, who had received standard therapy previously if available. This analysis set includes the 55 patients on which approval of larotrectinib was based. Larotrectinib was administered orally (capsule or liquid formulation), on a continuous 28-day schedule, to adults mostly at a dose of 100 mg twice daily, and to paediatric patients mostly at a dose of 100 mg/m 2 (maximum of 100 mg) twice daily. The primary endpoint was objective response as assessed by local investigators in an intention-to-treat analysis. Contributing trials are registered with ClinicalTrials.gov, NCT02122913 (active not recruiting), NCT02637687 (recruiting), and NCT02576431 (recruiting).Findings Between May 1, 2014, and Feb 19, 2019, 159 patients with TRK fusion-positive cancer were enrolled and treated with larotrectinib. Ages ranged from less than 1 month to 84 years. The proportion of patients with an objective response according to investigator assessment was 121 (79%, 95% CI 72-85) of 153 evaluable patients, with 24 (16%) having complete responses. In a safety population of 260 patients treated regardless of TRK fusion status, the most common grade 3 or 4 larotrectinib-related adverse events were increased alanine aminotransferase (eight [3%] of 260 patients), anaemia (six, 2%), and decreased neutrophil count (five [2%]). The most common larotrectinib-related serious adverse events were increased alanine aminotransferase (two [<1%] of 260 patients), increased aspartate aminotransferase (two [<1%]), and nausea (two [<1%]). No treatment-related deaths occurred.Interpretation These data confirm that TRK fusions define a unique molecular subgroup of advanced solid tumours for which larotrectinib is highly active. Safety data indicate that long-term administration of larotrectinib is feasible.Funding Bayer and Loxo Oncology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Nevertheless, entrectinib and lartotrectinib have demonstrated activity in patients with solid tumors with NTRK fusion”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“In this trial, 8 of 159 patients had colon cancer”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“with a median duration of 3.7 months.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“4 patients with colon cancer had a response to therapy”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“and the FDA has approved their use for these patients.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“Two therapies, larotrectinib and entrectinib, are FDA-approved for use in CRC with NTRK mutation.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“Based on the efficacy across tumor types, larotrectinib was FDA-approved for tumors with NTRK fusions, including CRC.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Self-citationAlectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704795 · Cited by 2,527
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
NTRK fusion-positive cancers and TRK inhibitor therapy
Cocco, E., Scaltriti, M., & Drilon, A. E. D. C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0113-0 · Cited by 1,521
Self-citationSkálová, A., Vaněček, T., Šíma, R., Laco, J., Weinreb, I., Perez‐Ordoñez, B., Stárek, I., Geierová, M., Simpson, R. H., Passador‐Santos, F., et al. (2010) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181d9efcc · Cited by 1,017
Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma
Tognon, C. E., Knezevich, S. R., Huntsman, D. D., Roskelley, C. D., Melnyk, N., Mathers, J. A., Becker, L. E., Carneiro, F., Macpherson, N. A., Horsman, D. E., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00180-0 · Cited by 908
Drilon, A. E. D. C., Siena, S., Ou, S. I., Patel, M. R., Ahn, M., Lee, J., Bauer, T. M., Farago, A. F., Wheler, J. J., Liu, S. V., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1237 · Cited by 833
Self-citation
Research works printed but not linked: 1
- Geoerger, 2019, Larotrectinib efficacyand safety in pediatric patients with TRK fusion cancer, Pediatr Blood Cancer, 66, S4
Cited by
Sorted by citations
Items 301–400 of 1,000
Levis, M., Gastino, A., Giorgi, G. D., Mantovani, C., Bironzo, P., Mangherini, L., Ricci, A. A., Ricardi, U., Cassoni, P., & Bertero, L. (2023) · Cancers · doi:10.3390/cancers15184622 · Cited by 19
TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions
Roviello, G., D’Angelo, A., Sciortino, M., Mini, E., Nobili, S., Logu, F. D., & Massi, D. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103011 · Cited by 19
Peng, H., Huang, R., Wang, K., Wang, C., Li, B., Guo, Y., Li, M., Zhang, D., Hua, D., Chen, H., et al. (2020) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2020.11.005 · Cited by 19
New Insights into the Pathogenesis of Systemic Mastocytosis
Li, Z. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094900 · Cited by 19
Allignet, B., Meurgey, A., Bouhamama, A., Karanian, M., Méeus, P., Vaz, G., Gouin, F., Moncharmont, C., Prapant, S., Waïssi, W., et al. (2021) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2021.07.008 · Cited by 19
Molecular Landscape in Infant High-Grade Gliomas: A Single Center Experience
Ruscio, V. D., Carai, A., Baldo, G. D., Vinci, M., Cacchione, A., Miele, E., Rossi, S., Antonelli, M., Barresi, S., Caulo, M., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12020372 · Cited by 19
New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HER2
Olmedo, M. E., Cervera, R., Cabezón‐Gutiérrez, L., Lage, Y., de la Fuente, E. C., Rueda, A. G., Mielgo-Rubio, X., Trujillo-Reyes, J. C., & Couñago, F. (2022) · World Journal of Clinical Oncology · doi:10.5306/wjco.v13.i4.276 · Cited by 19
Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers
Boilève, A., Verlingue, L., Hollebecque, A., Boige, V., Ducreux, M. P., & Malka, D. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1896703 · Cited by 18
TrkB/BDNF Signaling Could Be a New Therapeutic Target for Pancreatic Cancer
Oyama, Y., Nagao, S., Lin, N., Yanai, K., Umebayashi, M., Nakamura, K., Nagai, S., Fujimura, A., Yamasaki, A., Nakayama, K., et al. (2021) · Anticancer Research · doi:10.21873/anticanres.15205 · Cited by 18
Chen, J., Xu, C., Lv, J., Lu, W., Zhang, Y., Wang, D., & Song, Y. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-566 · Cited by 18
Gouda, M. A., Thein, K. Z., & Hong, D. S. (2024) · Cancers · doi:10.3390/cancers16193395 · Cited by 18
Self-citationCui, X., Huang, T., Jiang, T., & Wang, H. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217540 · Cited by 18
NTRK Fusion–Positive Thyroid Carcinoma: From Diagnosis to Targeted Therapy
Marczyk, V. R., Fazeli, S., Dadu, R., Busaidy, N. L., Iyer, P. C., Hu, M. I.-N., Sherman, S. I., Hamidi, S., Hosseini, S. M., Williams, M. D., et al. (2025) · JCO Precision Oncology · doi:10.1200/po.24.00321 · Cited by 18
Self-citationBasket trials: From tumour gnostic to tumour agnostic drug development
Dittrich, C. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102082 · Cited by 18
Tarantino, P., Mazzarella, L., Marra, A., Trapani, D., & Curigliano, G. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102169 · Cited by 18
Differential diagnosis and treatment of salivary secretory carcinoma and acinic cell carcinoma
Pang, Y., Sun, L., Liu, H., & Ma, J. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105370 · Cited by 18
The Utility of Endoscopic-Ultrasonography-Guided Tissue Acquisition for Solid Pancreatic Lesions
Tanaka, H., & Matsusaki, S. (2022) · Diagnostics · doi:10.3390/diagnostics12030753 · Cited by 18
Valderrábano, P., Eszlinger, M., Stewardson, P., & Paschke, R. (2023) · Clinical Endocrinology · doi:10.1111/cen.14882 · Cited by 18
Nanomedicine for targeting the lung cancer cells by interpreting the signaling pathways
Habeeb, M., Kareem, T. A., Deepthi, K. L., Khot, V. S., Woon, Y. H., & Pawar, S. S. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103865 · Cited by 17
Latest Advances in the Management of Pediatric Gastrointestinal Stromal Tumors
Andrzejewska, M., Czarny, J., & Derwich, K. (2022) · Cancers · doi:10.3390/cancers14204989 · Cited by 17
Genomics-Driven Precision Medicine in Pediatric Solid Tumors
Suthapot, P., Chiangjong, W., Chaiyawat, P., Choochuen, P., Pruksakorn, D., Sangkhathat, S., Hongeng, S., Anurathapan, U., & Chutipongtanate, S. (2023) · Cancers · doi:10.3390/cancers15051418 · Cited by 17
Combinatorial hypofractionated radiotherapy and pembrolizumab in anaplastic thyroid cancer
Tan, J. S. H., Tay, T. K. Y., Ong, E. H. W., Fehlings, M., Tan, D. S.-W., Sukma, N. B., Chen, E. X., Sng, J.-H., Yip, C., Lim, K. H., et al. (2024) · European Thyroid Journal · doi:10.1530/etj-23-0144 · Cited by 17
Current and emerging sequencing-based tools for precision cancer medicine
Edsjö, A., Gisselsson, D., Staaf, J., Holmquist, L., Fioretos, T., Cavelier, L. B., & Rosenquist, R. (2024) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2024.101250 · Cited by 17
Mascarenhas, L., DuBois, S. G., Albert, C. M., Bielack, S., Orbach, D. H., Federman, N. C., Geoerger, B., Nagasubramanian, R., Zhang, Y., Chisholm, J., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco.24.00848 · Cited by 17
Self-citationCurrent and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy
Román, M. S., Pozas, J., Molina‐Cerrillo, J., Gómez, J., Pian, H. G., Pozas, M., Carrato, A., Grande, E., & Alonso‐Gordoa, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144951 · Cited by 17
Diagnostik und Therapie von Tumoren mit NTRK-Genfusionen
Stenzinger, A., van Tilburg, C. M., Tabatabai, G., Länger, F. P., Graf, N. M., Griesinger, F., Heukamp, L. C., Hummel, M., Klingebiel, T. E., Hettmer, S., et al. (2020) · Der Pathologe · doi:10.1007/s00292-020-00864-y · Cited by 17
Self-citationEvaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion
Filippi, R., Depetris, I., & Satolli, M. A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1876664 · Cited by 17
Feeney, L., Jain, Y., Beasley, M. R., Donnelly, O., Kong, A. H., Molerón, R., Nallathambi, C., Rolles, M. J., Sanghera, P., Tin, A., et al. (2021) · Cancers · doi:10.3390/cancers13174336 · Cited by 17
The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncology—When and Why?
Kaczmarska, A., Śliwa-Tytko, P., Lejman, M., & Zawitkowska, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222112089 · Cited by 17
Tropomyosin-Related Kinase Fusions in Gastrointestinal Stromal Tumors
Lee, J. H., Shin, S., Choe, E., Kim, J., Hyung, W. J., Kim, H. S., Jung, M., Beom, S., Kim, T. I., Ahn, J. B., et al. (2022) · Cancers · doi:10.3390/cancers14112659 · Cited by 17
Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline
Yu, I. S., Aubin, F., Goodwin, R. A., Loree, J. M., Mather, C. A., Sheffield, B. S., Snow, S. L., & Gill, S. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221111705 · Cited by 17
Chu, Y., & Sadow, P. M. (2022) · Endocrine Pathology · doi:10.1007/s12022-022-09739-9 · Cited by 17
Catalano, F., Cremante, M., Dalmasso, B., Pirrone, C., D’Amato, A. L., Grassi, M., & Comandini, D. (2023) · Cancers · doi:10.3390/cancers15072074 · Cited by 16
The role of molecular testing in pancreatic cancer
Zhen, D. B., Safyan, R. A., Konick, E. Q., Nguyen, R., Pritchard, C. C., & Chiorean, E. G. (2023) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848231171456 · Cited by 16
Targeting the Clear Cell Sarcoma Oncogenic Driver Fusion Gene EWSR1::ATF1 by HDAC Inhibition
Mae, H., Outani, H., Imura, Y., Chijimatsu, R., Inoue, A., Kotani, Y., Yasuda, N., Nakai, S., Nakai, T., Takenaka, S., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0518 · Cited by 16
Management of Brain Metastases: A Review of Novel Therapies
Bellur, S. S., Khosla, A. A., Ozair, A., Kotecha, R. R., McDermott, M. W., & Ahluwalia, M. S. (2023) · Seminars in Neurology · doi:10.1055/s-0043-1776782 · Cited by 16
Colorectal Cancer: Genetic Underpinning and Molecular Therapeutics for Precision Medicine
Dosunmu, G. T., & Shergill, A. P. (2024) · Genes · doi:10.3390/genes15050538 · Cited by 16
Nakata, E., Osone, T., Ogawa, T., Taguchi, T., Hattori, K., & Kohsaka, S. (2024) · Cancer Medicine · doi:10.1002/cam4.7351 · Cited by 16
Targeting KRAS ‐mutant pancreatic cancer through simultaneous inhibition of KRAS , MEK, and JAK2
Miyazaki, S., Kitazawa, M., Nakamura, S., Koyama, M., Yamamoto, Y., Hondo, N., Kataoka, M., Tanaka, H., Takeoka, M., Komatsu, D. D., et al. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13751 · Cited by 16
Pitoia, F. (2021) · Clinical Case Reports · doi:10.1002/ccr3.3900 · Cited by 16
Tchekmedyian, V. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2021.05.011 · Cited by 16
Intracranial Metastatic Disease: Present Challenges, Future Opportunities
Li, A. Y., Gaebe, K., Jerzak, K. J., Cheema, P. K., Sahgal, A., & Das, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.855182 · Cited by 16
Huygens, S. A., Vellekoop, H., Versteegh, M., Santi, I., Szilberhorn, L., Zelei, T., Nagy, B., Tsiachristas, A., Koleva‐Kolarova, R., Wordsworth, S., et al. (2022) · Value in Health · doi:10.1016/j.jval.2022.08.006 · Cited by 16
Larotrectinib induces autophagic cell death through AMPK/mTOR signalling in colon cancer
Kong, W., Zhu, H., Zheng, S., Yin, G., Yu, P., Shan, Y., Liu, X., Ying, R., Zhu, H., & Ma, S. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17530 · Cited by 16
NTRK fusion events and targeted treatment of advanced radioiodine refractory thyroid cancer
Koehler, V. F., Achterfeld, J., Sandner, N., Koch, C., Wiegmann, J. P., Ivanyi, P., Käsmann, L., Pusch, R., Wolf, D. G. F., Chirica, M., et al. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05134-x · Cited by 16
Toward Targeted Therapies in Oesophageal Cancers: An Overview
Bregni, G., & Beck, B. (2022) · Cancers · doi:10.3390/cancers14061522 · Cited by 15
Regulating Tumorigenicity and Cancer Metastasis through TRKA Signaling
Fan, Y., Zhang, B., Du, X., Wang, B., Yan, Q., Guo, L., & Yao, W. (2023) · Current Cancer Drug Targets · doi:10.2174/1568009623666230904150957 · Cited by 15
Toledo, B., Deiana, C., Scianò, F., Brandi, G., Marchal, J. A., Perán, M., & Giovannetti, E. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2319340 · Cited by 15
Li, Z., Lu, W., Yin, F., & Huang, A. C. C. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.101965 · Cited by 15
Jerkovich, F., Capalbo, S., Abelleira, E., & Pitoia, F. (2024) · Endocrine · doi:10.1007/s12020-024-03867-4 · Cited by 15
Current status of molecular diagnostics for lung cancer
Имянитов, Е. Н., Преображенская, Е. В., & Орлов, С. В. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00244 · Cited by 15
Witte, D. P., Pretzell, I., Reißig, T. M., Stein, A., Velthaus, J.-L., Alig, A. H. S., Bohnenberger, H., Knödler, M., Kurreck, A., Sulzer, S., et al. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05954-5 · Cited by 15
Advances in Novel Targeted Therapies for Pancreatic Adenocarcinoma
Hoang, T. A., & Tsang, E. S. (2025) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-024-01149-w · Cited by 15
Resected High-Risk Rectal GIST Harboring NTRK1 Fusion: a Case Report and Review of the Literature
Peixoto, R. D., Medeiros, B. A., & Cronemberger, E. H. (2020) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-020-00423-x · Cited by 15
Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes
Zhang, C., Li, M., Lin, Y., & Gao, Q. (2020) · Current Gene Therapy · doi:10.2174/1566523220666200628014530 · Cited by 15
Tian, T., Huang, S., Dai, H., Qi, M., Liu, B., & Huang, R. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac600 · Cited by 15
Pollack, M. L. H., Keating, K. N., Wissinger, E., Jackson, L., Sarnes, E., & Cuffel, B. J. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1847057 · Cited by 15
Challenges, opportunities, and innovative statistical designs for precision oncology trials
Yin, J., Shen, S., & Shi, Q. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-356 · Cited by 14
Kanai, M. (2022) · Current Oncology · doi:10.3390/curroncol29100573 · Cited by 14
Carton, M., Castillo, J. P. D., Colin, J.-B., Kurtinecz, M., Feuilly, M., Pierron, G., Arvis, P., Khadir, S. K., Sparber‐Sauer, M., & Orbach, D. H. (2023) · Future Oncology · doi:10.2217/fon-2023-0114 · Cited by 14
Prevalence and clinico-genomic characteristics of patients with TRK fusion cancer in China
Xu, Y., Shi, X., Wang, W., Zhang, L., Cheung, S., Rudolph, M., Brega, N. M., Dong, X., Qian, L., Wang, L., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00427-3 · Cited by 14
Malik, P., Rani, R., Solanki, R., Patel, V. H., & Mukherjee, T. K. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00171 · Cited by 14
Analysis of CD74 Occurrence in Oncogenic Fusion Proteins
(2023) · doi:10.3390/ijms242115981 · Cited by 14
Ha, H., Lee, H. Y., Kim, J. H., Kim, D. Y., An, H. J., Bae, S., Park, H.-S., & Kang, J. H. (2024) · Cancer Research and Treatment · doi:10.4143/crt.2024.128 · Cited by 14
Sreenivasan, S., Jiwani, R. A., White, R., Bakalov, V., Moll, R., Liput, J., & Greenberg, L. (2025) · Current Oncology · doi:10.3390/curroncol32040232 · Cited by 14
Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer
Abdayem, P., & Planchard, D. (2021) · European Respiratory Review · doi:10.1183/16000617.0294-2020 · Cited by 14
de la Fouchardière, C., Wassermann, J., Calcagno, F., Bardet, S., Ghuzlan, A. A., Borget, I., Borson‐Chazot, F., Cao, C. D., Buffet, C., Zerdoud, S., et al. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.06.009 · Cited by 14
The Next Frontier in Pancreatic Cancer: Targeting the Tumor Immune Milieu and Molecular Pathways
Yin, C., Alqahtani, A. J., & Noel, M. S. (2022) · Cancers · doi:10.3390/cancers14112619 · Cited by 14
Current Targeted Therapy Options in the Treatment of Cholangiocarcinoma: A Literature Review
Proskuriakova, E., & Khedr, A. (2022) · Cureus · doi:10.7759/cureus.26233 · Cited by 14
Neuroimmune crosstalk and its impact on cancer therapy and research
Sharawy, I. (2022) · Discover Oncology · doi:10.1007/s12672-022-00547-5 · Cited by 14
Prevalence of NTRK Fusions in Canadian Solid Tumour Cancer Patients
Silvertown, J. D., Lisle, C., Semenuk, L., Knapp, C., Jaynes, J., Berg, D., Kaul, N., Lachapelle, J., Richardson, L., Speevak, M. D., et al. (2022) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-022-00617-y · Cited by 14
Adenocarcinomas of the Lung and Neurotrophin System: A Review
Rícci, A., Salvucci, C., Castelli, S., CARRATURO, A., Vitis, C. D., & D’Ascanio, M. (2022) · Biomedicines · doi:10.3390/biomedicines10102531 · Cited by 14
Martineau, C., Turcotte, M.-K., Otis, N., Provost, F., Themens, L., Guay, M., Letarte, N., & Adam, J. (2022) · Supportive Care in Cancer · doi:10.1007/s00520-022-07401-y · Cited by 14
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer
Ricciuti, B., Mira, A., Andrini, E., Scaparone, P., Michelina, S. V., Pecci, F., Cantini, L., Giglio, A. D., Lamberti, G., Ambrogio, C., et al. (2022) · Drugs in Context · doi:10.7573/dic.2022-7-4 · Cited by 14
Shin, J. E., An, H. J., Park, H. S., Kim, H., & Shim, B. Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.976450 · Cited by 14
Bueno, F., Smulever, A., Califano, I., Guerra, J. L., Grecco, A. D., Carrera, J. M., Giglio, R., Rizzo, M., Lingua, A., Voogd, A. I., et al. (2023) · Endocrine · doi:10.1007/s12020-022-03295-2 · Cited by 14
Schraa, S. J., Stelloo, E., Laclé, M. M., Swennenhuis, J. F., Brosens, L. A. A., Fijneman, R. J. A., Feitsma, H., Koopman, M., de Leng, W. W. J., Vink, G. R., et al. (2023) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-023-03538-1 · Cited by 14
Verburg, F. A., Amthauer, H., Binse, I., Brink, I., Buck, A. K., Darr, A., Dierks, C., Koch, C., König, U. M., Kreissl, M. C., et al. (2021) · Hormone and Metabolic Research · doi:10.1055/a-1380-4154 · Cited by 14
Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion
Mortensen, L. J., Ordulu, Z., Dagogo‐Jack, I., Bossuyt, V., Winters, L. N., Taghian, A. G., Smith, B. L., Ellisen, L. W., Kiedrowski, L. A., Lennerz, J. K., et al. (2021) · The Oncologist · doi:10.1002/onco.13880 · Cited by 14
New Tyrosine Kinase Inhibitors for the Treatment of Gastrointestinal Stromal Tumors
Serrano, C., & Bauer, S. (2022) · Current Oncology Reports · doi:10.1007/s11912-021-01165-0 · Cited by 14
TRK Inhibition with Entrectinib in Metastatic Salivary Secretory Carcinoma (SC): A Case Report
Ernst, M. S., Lysack, J. T., Hyrcza, M. D., Chandarana, S. P., & Hao, D. (2022) · Current Oncology · doi:10.3390/curroncol29060314 · Cited by 13
Cui, Z., Zhai, Z., Xie, D., Wang, L., Cheng, F., Lou, S., Zou, F., Pan, R., Chang, S., Yao, H., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1329409 · Cited by 13
Labiano, I., Huerta, A. E., Alsina, M., Arasanz, H., Castro, N., Mendaza, S., Lecumberri, A., González‐Borja, I., Guerrero‐Setas, D., Patiño‐García, A., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-67235-y · Cited by 13
Hou, X., Shi, W., Luo, W., Luo, Y., Huang, X., Li, J., Ji, N., & Chen, Q. (2024) · Biomolecules · doi:10.3390/biom14101297 · Cited by 13
Dietz, M. S., Al‐Ibraheemi, A., Davis, J. L., Hawkins, C. M., Craig, B. T., Dasgupta, R. A., Geller, D. S., Shulman, D. S., Cohen‐Gogo, S., Gupta, A. K., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.7063 · Cited by 13
Self-citationVico, T. D., Martínez-Amores, B., Mihic-Góngora, L., Jiménez‐Fonseca, P., Peinado, P., Torrente, I. G., Muñoz-Nájar, A. G., & Durán, M. (2025) · Cancers · doi:10.3390/cancers17111800 · Cited by 13
Schoenmaekers, J. J. A. O., Paats, M. S., Dingemans, A. C., & Hendriks, L. E. L. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-459 · Cited by 13
Chu, Y., & Sadow, P. M. (2021) · Diagnostic histopathology · doi:10.1016/j.mpdhp.2021.03.003 · Cited by 13
Cardiovascular Complications Associated with Contemporary Lung Cancer Treatments
Sase, K., Fujisaka, Y., Shoji, M., & Mukai, M. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00869-6 · Cited by 13
Yang, J. C., Brose, M. S., de Castro, G., Kim, E. S., Lassen, U., Leyvraz, S., Pappo, A. S., López‐Ríos, F., Reeves, J. A., Fellous, M. M., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09687-x · Cited by 13
Self-citationKlink, A. J., Kavati, A., Gassama, A., Kozlek, T., Gajra, A., & Antoine, R. (2022) · Targeted Oncology · doi:10.1007/s11523-022-00887-w · Cited by 13
Lu, L., Wang, S., Shen, H., Zhang, F., Ma, F., Shi, Y., & Ning, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1108586 · Cited by 13
Cost-Efficient Detection of NTRK1/2/3 Gene Fusions: Single-Center Analysis of 8075 Tumor Samples
Romanko, A. A., Mulkidzhan, R., Tiurin, V. I., Saitova, E. S., Преображенская, Е. В., Krivosheyeva, E. A., Mitiushkina, N. V., Шестакова, А. Д., Белогубова, Е. В., Ivantsov, A. O., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814203 · Cited by 13
How selecting best therapy for metastatic NTRK fusion-positive non-small cell lung cancer?
Ekman, S. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-434 · Cited by 13
Supportive care for new cancer therapies
Rapoport, B. L., Cooksley, T., Johnson, D. B., & Anderson, R. (2021) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000736 · Cited by 13
Pursuing Precision: Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors
Bellantoni, A. J., & Wagner, L. M. (2021) · Cancers · doi:10.3390/cancers13143531 · Cited by 13
Silverman, I. M., Li, M., Murugesan, K., Krook, M. A., Javle, M. M., Kelley, R. K., Borad, M. J., Roychowdhury, S., Meng, W., Yilmazel, B., et al. (2022) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2021.12.012 · Cited by 13
Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas
Hsu, R. C., Baca, Y., Xiu, J., Wang, R., Bodor, J. N., Kim, C., Khan, H., Mamdani, H. M., Nagasaka, M., Puri, S., et al. (2021) · Oncotarget · doi:10.18632/oncotarget.28132 · Cited by 13
Kwon, J. S., Tinker, A. V., Santos, J. L., Compton, K., Sun, S. B., Schrader, K. A., & Karsan, A. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00033 · Cited by 13
Sarradin, V., Digue, L., Vergèz, S., Thariat, J., Fakhry, N., Chabrillac, E., Bensadoun, R. J., Ferrand, F., & Even, C. (2023) · European Annals of Otorhinolaryngology Head and Neck Diseases · doi:10.1016/j.anorl.2023.11.004 · Cited by 13
Metadata
- Authors
- Hong, D. S., DuBois, S. G., Kummar, S., Farago, A. F., Albert, C. M., Rohrberg, K. S., van Tilburg, C. M., Nagasubramanian, R., Berlin, J. D., Federman, N., Mascarenhas, L., Geoerger, B., Dowlati, A., Pappo, A. S., Bielack, S., Doz, F., McDermott, R., Patel, J. D., Schilder, R. J., Tahara, M., Pfister, S. M., Witt, O., Ladanyi, M., Rudzinski, E. R., Nanda, S., Childs, B. H., Laetsch, T. W., Hyman, D. M., & Drilon, A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- Stanford Medicine (US)
- Massachusetts General Hospital (US)
- Seattle Children's Hospital (US)
- University of Copenhagen (DK)
- Vanderbilt University Medical Center (US)
- University of California, Los Angeles (US)
- University of Southern California (US)
- Université Paris-Saclay (FR)
- University Hospitals Cleveland Medical Center (US)
- St. Jude Children's Research Hospital (US)
- Olgahospital (DE)
- Université Paris Descartes (FR)
- Cancer Trials Ireland (IE)
- University of Chicago (US)
- Thomas Jefferson University (US)
- National Cancer Center Hospital East (JP)
- German Cancer Research Center (DE)
- Memorial Sloan Kettering Cancer Center (US)
- Bayer (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- Drilon, Alexander
- ORCID
- Hong, David S
- DuBois, Steven G
- Kummar, Shivaani
- Farago, Anna F
- Albert, Catherine M
- Rohrberg, Kristoffer S
- Nagasubramanian, Ramamoorthy
- Berlin, Jordan D
- Federman, Noah
- Mascarenhas, Leo
- Geoerger, Birgit
- Dowlati, Afshin
- Pappo, Alberto S
- Bielack, Stefan
- Doz, François
- McDermott, Ray
- Patel, Jyoti D
- Tahara, Makoto
- Pfister, Stefan M
- Witt, Olaf
- Ladanyi, Marc
- Rudzinski, Erin R
- Nanda, Shivani
- Childs, Barrett H
- Laetsch, Theodore W
- Hyman, David M
- Drilon, Alexander
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 21
- Issue
- 4
- Pages
- 531-540
- ISSN
- 1470-2045 (ISSN-L)
- PMC
- PMC7497841
- OpenAlex
- W3008107700
- Cited by
- 1,028
- References
- 25
- Citations by year
- 2026: 106 · 2025: 148 · 2024: 162 · 2023: 178 · 2022: 202 · 2021: 171 · 2020: 60
- FWCI
- 86.25
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Loxo Oncology
- Bayer Corporation
- Bayer Fund
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- larotrectinib, TRK inhibitors, objective response rate, long-term safety, adverse events, childhood cancer, adult cancer, metastatic cancer, pooled analysis of clinical trials, alanine aminotransferase elevation, neutropenia, anemia, complete response, dose-limiting toxicity
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Neoplasms, Proteins, Pyrazoles, Pyrimidines, Vesicular Transport Proteins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
